Access and equity to cancer clinical trials in Oregon
Emmanuella Oyogoa(Oregon Health & Science University), Eneida R. Nemecek(Oregon Health & Science University), David Castro‐Díaz(Oregon Health Authority), Eliana Turk(Oregon Health & Science University), Michael Crespo(Portland State University), K Mayer(Oregon Health & Science University), Trisha Marsh(Oregon Health & Science University), Jackilen Shannon(Oregon Health & Science University)
Cited by 0
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
|Blood|2016|333
The genomic landscape of juvenile myelomonocytic leukemia
|Nature Genetics|2015|310